BenevolentAI
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company.
Launch date
Employees
Market cap
€105m
Enterprise valuation
€67m (Public information from Sep 2024)
Share price
€0.71 BAI.AS
Company register number 09781806
London England (HQ)
Financials
Estimates*
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.9m | 4.6m | 10.6m | 7.3m | 23.1m | 22.0m | 39.2m |
| % growth | 49 % | (33 %) | 128 % | (31 %) | 216 % | (5 %) | 78 % |
| EBITDA | (62.2m) | (83.5m) | (192m) | (69.9m) | (44.2m) | (40.5m) | (17.7m) |
| % EBITDA margin | (900 %) | (1806 %) | (1823 %) | (953 %) | (191 %) | (184 %) | (45 %) |
| Profit | (55.4m) | (86.5m) | (164m) | (63.3m) | (29.9m) | (29.9m) | (9.9m) |
| % profit margin | (802 %) | (1870 %) | (1552 %) | (864 %) | (129 %) | (136 %) | (25 %) |
| EV / revenue | - | - | 22.1x | 5.1x | 2.3x | 0.9x | 0.4x |
| EV / EBITDA | - | - | -1.2x | -0.5x | -1.2x | -0.5x | -0.9x |
| R&D budget | 72.5m | 47.1m | 65.1m | 60.8m | - | - | - |
| R&D % of revenue | 1049 % | 1018 % | 616 % | 829 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$115m Valuation: $2.1b 268.8x EV/LTM Revenues | Late VC | ||
* | $90.0m Valuation: $1.0b 111.0x EV/LTM Revenues | Late VC | |
N/A | Support Program | ||
* | €300m Valuation: €1.5b 181.0x EV/LTM Revenues -20.1x EV/LTM EBITDA | SPAC IPO | |
* | €135m Valuation: €1.5b 181.0x EV/LTM Revenues -20.1x EV/LTM EBITDA | SPAC Private Placement | |
| Total Funding | €412m | ||
Related Content
Recent News about BenevolentAI
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.